Skip to main content

Ranbaxy Labs subsidiary to launch hyperparathyroidism generic


PRINCETON, N.J. The U.S. subsidiary of an Indian generic drug maker will launch an authorized generic version of a hyperparathyroidism drug.

Ranbaxy Pharmaceuticals, part of Gurgaon, India-based Ranbaxy Labs, launched calcitrol capsules and oral solution. The drug is an authorized generic of Validus Pharmaceuticals’ Rocaltrol, which had sales of $70 million for the 12 months ended in June, according to IMS Health data.

The drug is used to manage secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure not yet on dialysis, as well as hypocalcemia and resulting metabolic bone disease in patients undergoing chronic renal dialysis and other forms of thyroid disease.

Ranbaxy is launching the drug under an agreement with Validus. An authorized generic is a branded drug marketed under its generic name at a lower price, often by a third-party company.

“Ranbaxy was very pleased to be selected by Validus as their distribution partner for an authorized generic version of Rocaltrol,” Ranbaxy Pharmaceuticals VP sales and distribution Jim Meehan said in a statement. “This product represents an excellent commercial opportunity for Ranbaxy which will increase our visibility and presence in the U.S. healthcare system.”

This ad will auto-close in 10 seconds